Get the weekly note

Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.

ETFIQetfiq.com · independent ETF data

VCLT vs XBI: how they differ

VCLT and XBI hold 0% of their weight in the same names, and XBI returned more over the year.

Vanguard Long-Term Corporate Bond Index Fund and State Street(R) SPDR(R) S&P(R) Biotech ETF.

What they hold in common

By the books each fund has filed, VCLT and XBI hold 0% of their money in the same securities at the same weight.

Largest positions each one holds and the other does not
Only in VCLTOnly in XBI
Anheuser-Busch Cos LLC / Anheuser-Busch 0.38%Apogee Therapeutics Inc 1.49%
CVS Health Corp 0.34%Moderna Inc 1.41%
Meta Platforms Inc 0.29%Twist Bioscience Corp 1.41%
Boeing Co/The 0.27%Oruka Therapeutics Inc 1.38%
Pfizer Investment Enterprises Pte Ltd 0.27%Kymera Therapeutics Inc 1.36%
Amazon.com Inc 0.26%Viking Therapeutics Inc 1.31%
Oracle Corp 0.24%Praxis Precision Medicines Inc 1.29%
AT&T Inc 0.24%Erasca Inc 1.27%

Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and May 31, 2026.

VCLT and XBI on the fields both publish, as of Sep 12, 2026. Source: ETFIQ.
VCLT
Vanguard Long-Term Corporate Bond Index Fund
XBI
State Street(R) SPDR(R) S&P(R) Biotech ETF
Where it sitsCore index fundCore index fund
IssuerVanguardState Street
What it isLong-Term Corporate BondSPDR S&P Biotech
Total return, 1 year−4.8%+64.0%
S&P 500 over the same days+17.5%+17.5%
Gap to the S&P 500−22.3 pts+46.5 pts
Expense ratio0.03%0.35%
Holdings2775150

VCLT in plain words

VCLT is a bond fund tracking the Long-Term Corporate Bond. Over the year to Sep 11, 2026 it returned −4.8% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.03% a year. It sat 18.1% below its high of Sep 22, 2021 on Sep 11, 2026.

XBI in plain words

XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.

Questions people ask

Which returned more over the last year, VCLT or XBI?
In the year to Sep 12, 2026, with distributions reinvested, VCLT returned −4.8% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
Which is cheaper, VCLT or XBI?
VCLT charges 0.03% a year and XBI charges 0.35%, so VCLT is cheaper. Fees come from each fund's prospectus.

Other comparisons

Where to next

Where these figures came from

ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.

VCLT against XBI, ETFIQ, data as of Sep 12, 2026. Every figure is arithmetic on a named public source; the method is at etfiq.com/methodology. A comparison is not a recommendation.

Cite this page. ETFIQ, VCLT against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/VCLT-XBI Free to use with attribution; the underlying files are at Open data.

A comparison is not a recommendation. Standards and sources